Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody

Br J Dermatol. 2010 Feb 1;162(2):337-44. doi: 10.1111/j.1365-2133.2009.09484.x. Epub 2009 Aug 29.


Background: To date, no series has analysed long-term outcome in patients with polymyositis/dermatomyositis (PM/DM) with anti-PM-Scl antibody.

Objectives: The aims of the present study were: (i) to assess clinical features and long-term outcome, including organ complications, functional course and mortality rate, in patients with isolated PM/DM with anti-PM-Scl antibody; and (ii) to evaluate prevalence, characteristics and long-term outcome of interstitial lung disease (ILD) in patients with isolated PM/DM with anti-PM-Scl antibody.

Methods: The medical records of 20 consecutive patients with isolated PM/DM with anti-PM-Scl antibody were reviewed.

Results: Two patients (10%) achieved remission of PM/DM, whereas 14 (70%) improved and four (20%) had a worsened clinical status. Short-term recurrences (during tapering of therapy) occurred in nine patients and long-term recurrences (after discontinuation of therapy) in three patients. Moreover, patients with PM/DM with anti-PM-Scl antibody exhibited severe complications, as follows: oesophageal involvement (n = 4) requiring enteral feeding in three cases, ventilatory insufficiency (n = 3) requiring mechanical ventilation in two cases; three other patients had cancer. Interestingly, patients with PM/DM with anti-PM-Scl antibody often presented symptoms that are usually found in antisynthetase syndrome, i.e. hyperkeratotic rhagadiform hand symptoms (n = 2; 10%), Raynaud's phenomenon (n = 8; 40%), arthralgia/arthritis (n = 7; 35%) and ILD (n = 12; 60%). In our cohort, the associated ILD often required combined therapy of steroids and immunosuppressive agents.

Conclusions: Our series suggests that the presence of anti-PM-Scl antibody is not a good prognostic factor in patients with PM/DM, as there appears to be an association with lung and oesophageal involvement; in addition, anti-PM-Scl antibody may coexist with malignancy in patients with PM/DM. Furthermore, anti-PM-Scl antibody-positive patients with PM/DM often exhibit 'mechanic's hands', Raynaud's phenomenon and joint involvement. Our latter findings raise the possibility that the immunogenetic background influences the autoantibody status of these patients; HLA-DR3 has, in fact, been found in association with antisynthetase syndrome antibodies and with anti-PM-Scl antibodies.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Anti-Idiotypic / blood
  • Antibodies, Anti-Idiotypic / immunology*
  • Biomarkers / blood
  • Dermatomyositis / complications
  • Dermatomyositis / drug therapy
  • Dermatomyositis / immunology*
  • Drug Therapy, Combination
  • Exoribonucleases / blood
  • Exoribonucleases / immunology*
  • Exosome Multienzyme Ribonuclease Complex
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lung Diseases, Interstitial / etiology
  • Lung Diseases, Interstitial / immunology
  • Male
  • Middle Aged
  • Nuclear Proteins / blood
  • Nuclear Proteins / immunology*
  • Prognosis
  • Steroids / therapeutic use
  • Time Factors
  • Young Adult


  • Antibodies, Anti-Idiotypic
  • Biomarkers
  • Immunosuppressive Agents
  • Nuclear Proteins
  • Steroids
  • Exoribonucleases
  • Exosome Multienzyme Ribonuclease Complex
  • EXOSC10 protein, human